Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database-Reference-Cited by-同舟云学术

Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database

Published:2021-11-29 Issue:24 Volume:10 Page:8754-8762
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Hu Fangyuan¹²,Zhai Yinghong³,Yuan Lei⁴^ORCID,Liang Jizhou¹,Xu Jinfang¹,Guo Xiaojing¹,Zhou Xiang³,Lin Zhen¹,Sun Jinhai⁴,Ye Xiaofei¹,He Jia¹³^ORCID

Affiliation:

1. Department of Health Statistics Second Military Medical University Shanghai China

2. Department of Medical Service Naval Hospital of Eastern theater Zhoushan China

3. Tongji University School of Medicine Shanghai China

4. Department of health management Second Military Medical University Shanghai China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4343

Reference24 articles.

1. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

2. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

3. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

4. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

5. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Adverse renal outcomes following targeted therapies in renal cell carcinoma: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-06-26

3. Rationale for immune checkpoint inhibitors plus targeted therapy for advanced renal cell carcinoma;Heliyon;2024-04

4. Nephrotoxicity in the Age of Immune Checkpoint Inhibitors: Mechanisms, Diagnosis, and Management;International Journal of Molecular Sciences;2023-12-28

5. Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study;Frontiers in Pharmacology;2023-10-31